A revolutionary approach to GLP-1s and obesity care.

Affordable GLP-1 access with a breakthrough pharmacy solution.
While GLP-1s have revolutionized healthcare, they come at a cost. Noom’s SmartRx pharmacy carve-out solution, an enhancement of Noom Med, provides transparent, discounted pricing on GLP-1 medications for weight loss, with the flexibility to set custom copays separate from other covered medications.

Bypass PBM intermediaries for cost-effective, uninterrupted medication access

Access branded GLP-1 medications at reduced prices and decide how to share costs with employees

Ensure rapid access to GLP-1 medications within 5 days to drive increased persistence anD better health outcomes
Higher ROI. Better outcomes. Healthier people.

Evidence-based protocols
Proven experience showing that while GLP-1 medications are an effective tool for weight management, their efficacy is significantly enhanced when paired with robust lifestyle interventions.
Reducing the yo-yo effect
A structured approach to medication tapering that begins with medication support, and balances medical needs and costs to avoid weight regain as part of the “yo-yo” cycle.
World class behavior change
We utilize our award-winning behavior change program as the foundation of our care model to enhance health outcomes and ensure lasting ROI.
Positive ROI accumulation
A proven track record of delivered, measurable health improvements and cost savings, providing partners with a 4.1X ROI over a three-year period.
Combining mind and medicine, for lasting health outcomes.

Obesity care clinicians provide personalized support from initial assessment to continuous care, including prescribing medications based on individual needs of each patient.

Members have access to health coaching, a supportive community, and a psychology-driven digital curriculum designed to foster lasting behavior change.

Patients are provided with the tools and resources necessary to allow clinicians to track progress and make timely, personalized adjustments to their treatment plan.

Embedded care pathway that provides tailored support to members taking a GLP-1 or other anti-obesity medication.
Real support leads to real results.
alternative to GLP-1s1
pairing Noom with an early GLP-1
vs a GLP-1 alone2
healthcare and cost
savings over 3 years3
The proof is in the members.
The all-in-one solution to healthy living and lower costs.
Bring Noom to your organization today.
By submitting this form, you consent to our Terms and Conditions.
- Third-party validated actuarial analysis, October 2024. This projection is based on a comparison to a status quo scenario where GLP-1 medication spending is uncontrolled. ROI may vary based on factors such as company size, employee health profiles, and current healthcare costs.
- Based on a retrospective study of self-reported data of pounds lost for active versus passive users who were offered the Noom program when being prescribed an early stage GLP-1.
- Third-party validated actuarial analysis, October 2024. This projection is based on a comparison to a status quo scenario where GLP-1 medication spending is uncontrolled. ROI may vary based on factors such as company size, employee health profiles, and current healthcare costs.